This is reported by Interfax with reference to the head of FMBA Veronika Skvortsova.
She recalled that Mir-19 has already passed the first and second phases of clinical trials and will be released in inhalation form, and now the agency is creating an analogue of the drug in the form of a spray.
A report with information about the second phase of clinical trials of the drug for registration with the FMBA is planned to be sent to the Ministry of Health in the second half of September.
Earlier, the agency announced the passage of the third stage of clinical trials of the world's first registered specific immunoglobulin against COVID-19 - we are talking about the drug Covid Globulin.